The recent withdrawal by Abbott Labs of its obesity drug, Meridia, and the rejection by the FDA of Arena Phamaceutical’s lorcaserin places even sharper focus on the continuing demand for effective obesity treatment. Currently, and possibly for some time to come, the clinical intervention in the management of obesity is largely dominated by surgical and device options.
The outlook for manufacturers remains strongly in favor of clinical options as the prevalence of obesity, and its essentially co-morbid partner, diabetes, increases steadily worldwide.
“Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2009-2019”, publishing October 2010 from MedMarket Diligence, details the current status of product development for drugs and devices for treatment of obesity and provides a global market forecast. See link for details.